Ras Effector RASSF10 locks the metabolic reprogramming mechanism in tumour cells
Implementing Organization
Principal Investigator
Prof. Sundarasamy Mahalingam
Indian Institute of Technology(IIT) Madras
About
Tumour development is a multistep process with different biological capabilities acquired at each stage. Deregulation in developmental pathways, including RAS, alters cell fate decisions. RASSF10, a member of novel nonenzymatic RAS effectors, is downregulated in 60% of cancers through hypermethylation. It inhibits cell proliferation, survival, and migration. RASSF10 downregulates GNL3L and IMPDH2 expression, which are overexpressed in many solid tumors and negatively correlate with patient survival. Understanding RASSF10's function is crucial for cancer treatment.
Indian Institute of Technology(IIT) Madras
Acces sibility Controls